Biosig Technologies, INC 8-K filings
BioSig Technologies is appealing Nasdaq's decision to delist its stock after failing to meet minimum bid price and equity requirements.
8-K: BioSig Technologies Appoints Frederick D. Hrkac as President and CEO, Replacing Kenneth L. Londoner
BioSig Technologies has appointed Frederick D. Hrkac as its new President and CEO, effective February 27, 2024, following the resignation of Kenneth L. Londoner.
BioSig Technologies has reported the resignation of its CFO and six board members, all effective within a week, with no indication of disagreements.
BioSig Technologies announces that its Near Field Tracking algorithm has been used in over 100 patient cases, showcasing its clinical adoption and ability to reduce ablation time.
BioSig Technologies initiated a workforce reduction, including the departure of key executives, to reduce annual cash burn by approximately 50%.
BioSig Technologies has initiated a workforce reduction, completed by January 31, 2024, to decrease annual cash burn by approximately 50%.
BioSig Technologies has completed a 1-for-10 reverse stock split, effective February 1, 2024, to reduce the number of outstanding shares.
BioSig Technologies is reducing its workforce and shifting its strategy to focus on business development and distribution partnerships to cut its cash burn by 50%.
BioSig Technologies has issued warrants allowing the purchase of common stock, exercisable after six months, with a termination date in five and a half years.